Skip to main content
SpringerLink
Log in

Adverse Haematological Effects of Ticlopidine

A Report of Four Cases

  • Case Reports
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394–405

    PubMed  CAS  Google Scholar 

  2. Harbison JW. Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the ticlopidine aspirin stroke study. Stroke 1992; 23: 1723–7

    Article  PubMed  CAS  Google Scholar 

  3. Davis SM, Donnan GA. Secondary prevention for stroke after CAPRIE and ESRS-2. Opinion 1. Cerebrovasc Dis 1998; 8: 73–5

    Article  PubMed  Google Scholar 

  4. Diener HC. Antiplatelet drugs in secondary prevention of stroke. Int J Clin Pract 1998; 52: 91–7

    PubMed  CAS  Google Scholar 

  5. Dyken ML. Secondary prevention for stroke after CAPRIE and ESRS-2. Opinion 2. Cerebrovasc Dis 1998; 8: 75–7

    PubMed  CAS  Google Scholar 

  6. Janzon L, Bergqvist D,Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301–8

    Article  PubMed  CAS  Google Scholar 

  7. Jackson MC, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 1998; 114(5 Suppl.): 666S–682S

    Article  PubMed  CAS  Google Scholar 

  8. Balsano F, Rizzon P, Violi F, et al, STAI Group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990; 82: 17–26

    Article  PubMed  CAS  Google Scholar 

  9. De Maat MP, Arnold AE, Van Buuren S, et al. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost 1996; 76: 166–70

    PubMed  Google Scholar 

  10. Noble S, Goa KL. Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging 1996; 8: 214–32

    Article  PubMed  CAS  Google Scholar 

  11. Tung C, Sauri D, Fintel D, et al. Management of high-risk subsets in unstable angina. Cardiol Clin 1999; 17: 415–37

    Article  PubMed  CAS  Google Scholar 

  12. Mazur W, Kaluza G, Kleiman NS. Antiplatelet therapy for treatment of acute coronary syndromes. Cardiol Clin 1999; 17: 345–57

    Article  PubMed  CAS  Google Scholar 

  13. Ito MK, Smith AR, Lee ML. Ticlopidine: a new platelet aggregation inhibitor. Clin Pharm 1992; 11: 603–17

    PubMed  CAS  Google Scholar 

  14. Haynes RB, Sandier RS, Larson EB, et al. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992; 152: 1376–80

    Article  PubMed  CAS  Google Scholar 

  15. Sanchez-Bisono JR, Gomez-Moli J, Escudero-Canto M. Probable ticlopidine-induced severe aplastic anemia and cholestatic hepatitis [letter]. Haematologica 1997; 82: 639

    PubMed  CAS  Google Scholar 

  16. Ceylan C, Kirimli O, Akarsu M, et al. Early ticlopidine-induced hepatic dysfunction, dermatitis and irreversible aplastic anemia after coronary stenting [letter]. Am J Hematol 1998; 59: 260

    Article  PubMed  CAS  Google Scholar 

  17. Martinez Perez-Balsa A, De Arce A, Castiella A, et al. Hepato-toxicity due to ticlopidine [letter]. Ann Pharmacother 1998; 32: 1250–1

    Article  Google Scholar 

  18. Iqbal M, Goenka P, Young MF, et al. Ticlopidine-induced cholestatic hepatitis: report of three cases and review of the literature. Dig Dis Sci 1998; 43: 2223–6

    Article  PubMed  CAS  Google Scholar 

  19. Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991; 337: 774–6

    Article  PubMed  CAS  Google Scholar 

  20. Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother 1993; 27: 1060–1

    PubMed  CAS  Google Scholar 

  21. Weiner P, Zidan F, Paz R. Severe aplastic anemia due to ticlopidine. Isr JMed Sci 1995; 31: 444–5

    CAS  Google Scholar 

  22. Shapiro CM, Walk D. Aplastic anemia associated with ticlopidine. Neurology 1996; 47: 300

    Article  PubMed  CAS  Google Scholar 

  23. Kao TW, Hung CC, Chen YC, et al. Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature. Acta Haematol 1997; 98: 211–3

    Article  PubMed  CAS  Google Scholar 

  24. Bennet CL, Kiss JE, Weinberg PD. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998 352: 1036–7

    Article  Google Scholar 

  25. Gur H, Wartenfeld R, Tanne D, et al. Ticlopidine-induced severe neutropenia. Postgrad Med J 1998; 74: 126–7

    Article  PubMed  CAS  Google Scholar 

  26. Love B, Biller J, Gentile M. Adverse haematological effects of ticlopidine: prevention, recognition and management. Drug Saf 1998; 19: 89–98

    Article  PubMed  CAS  Google Scholar 

  27. Muszkat M, Shapira MY, Sviri S, et al. Ticlopidine-induced thrombotic thrombocytopenic purpura. Pharmacotherapy 1998; 18:1352–5

    PubMed  CAS  Google Scholar 

  28. Yeh SP, Hsueh EJ, Wu H, et al. Ticlopidine-induced aplastic anemia. A case report and review of the literature. Ann Hematol 1998; 76: 87–90

    Article  PubMed  CAS  Google Scholar 

  29. Chen DK, Kim JS, Sutton DMC. Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature. Arch Intern Med 1999; 159: 311–4

    Article  PubMed  CAS  Google Scholar 

  30. Elangovan L. Thrombotic thrombocytopenic purpura associated with ticlopidine use [letter]. Arch Intern Med 1999; 159: 1624

    Article  PubMed  CAS  Google Scholar 

  31. Koornstra JJ, Loualidi A, de Vries CJ. Ticlopidine-induced thrombocytopenia. Neth J Med 1999; 54: 73–5

    Article  PubMed  CAS  Google Scholar 

  32. Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994; 28: 1236–8

    PubMed  CAS  Google Scholar 

  33. Szto GYF, Linnemeier TJ, Ball MW. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 1999; 83: 138–9

    Article  PubMed  CAS  Google Scholar 

  34. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222–62

    Article  PubMed  CAS  Google Scholar 

  35. Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321:501–7

    Article  PubMed  CAS  Google Scholar 

  36. Gent M, Blakeley JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–20

    Article  PubMed  CAS  Google Scholar 

  37. Gregorini L, Marco J, Fajadet J, et al. Ticlopidine and aspirin pretreatment coagulation and platelet activation during coronary dilatation procedures. J An Coll Cardiol 1997; 29: 13–20

    Article  CAS  Google Scholar 

  38. Van de Loo A, Nauck M, Noory E, et al. Enhancement of platelet inhibition of ticlopidine plus aspirin vs aspirin alone given prior to elective PTCA. Eur Heart J 1998; 19: 96–102

    Article  PubMed  Google Scholar 

  39. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet with anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–9

    Article  PubMed  CAS  Google Scholar 

  40. Ferrer F, Moraleda JM, Vicente V. Antithrombotic therapy after coronary-artery stenting [letter]. N Engl J Med 1999; 340: 1365–7

    Article  PubMed  CAS  Google Scholar 

  41. Licoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341: 319–27

    Article  Google Scholar 

  42. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

  43. Neumann FJ, Hall D, Schoming A. Neutropenia with ticlopidine plus aspirin [letter]. Lancet 1997; 24: 1552–3

    Article  Google Scholar 

  44. Haushofer A, Halbmayer WM, Prachar H. Neutropenia with ticlopidine plus aspirin [letter]. Lancet 1997; 15: 474–5

    Article  Google Scholar 

  45. De Gramont A, Canuel C, Krulik M, et al. Hematological toxicity of ticlopidine. Nouv Rev Fr Hematol 1982; 24: 35–7

    Google Scholar 

  46. Quaglini D, Venturoni L, Cretara G, et al. Reversible bone-marrow suppression primarily involving granulopoiesis following the use of ticlopidine. Haematologica 1982; 67: 940–1

    Google Scholar 

  47. Resegotti L, Pistone MA, Testa D, et al. Bone marrow culture in patients receiving ticlopidine treatment. Nouv Rev Fr Hematol 1985; 27: 19–22

    PubMed  CAS  Google Scholar 

  48. Marinella MA. Agranulocytosis associated with ticlopidine: a possible benefit with filgastrim. Ann Clin Lab Sci 1997; 27: 418–21

    PubMed  CAS  Google Scholar 

  49. Bahng H, Lee JH, Suh C, et al. Severe aplastic anemia induced by ticlopidine: report of two cases. J Korean Med Sci 1998; 13: 541–4

    PubMed  CAS  Google Scholar 

  50. Ochoa AB, Wolfe M, Lewis P, et al. Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement. Clin Cardiol 1998; 21: 304–7

    Article  PubMed  CAS  Google Scholar 

  51. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998; 1228: 541–4

    Google Scholar 

  52. Elias M, Reichaman N, Flatau E. Bone marrow aplasia associated with ticlopidine therapy [letter]. Am J Hematol 1993; 44: 289–91

    Article  PubMed  CAS  Google Scholar 

  53. Mallet L, Mallet J. Ticlopidine and fatal aplastic anemia in an elderly woman. Ann Pharmacother 1994; 28: 1169–71

    PubMed  CAS  Google Scholar 

  54. Dunn P. Aplastic anemia with ticlopidine therapy in two Chinese patients [letter]. Ann Pharmacother 1996; 30: 547

    PubMed  CAS  Google Scholar 

  55. Mataix R, Ojeda E, Perez M, et al. Ticlopidine and severe aplastic anaemia. Br J Haematol 1992; 80: 125–6

    Article  PubMed  CAS  Google Scholar 

  56. Thomson LEJ, Stewart JT. Ticlopidine induced agranulocytosis managed with granulocyte colony stimulating factor. N Z Med J 1998; 111:81–2

    PubMed  CAS  Google Scholar 

  57. Abou-Khalil WH, Lim LO, Yunnis AA, et al. Effects of ticlopidine, a new platelet antiaggregating agent, and its analogues on mitochondrial metabolism. Oxidative phosphorylation, protein synthesis and DNA polymerase activity. Biochem Pharmacol 1984; 33: 3893–8

    Article  PubMed  CAS  Google Scholar 

  58. Ono K, Kurohara K, Yoshihara M, et al. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol 1991; 37: 239–42

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, Section of Internal Medicine II, University of Ferrara, Via Savonarola 9, I-44100, Ferrara, Italy

    Massimo Gallerani, P. Donegà, G. B. Vigna & R. Fellin

  2. Department of Clinical and Experimental Medicine, Section of Internal Medicine I, University of Ferrara, Ferrara, Italy

    R. Manfredini

  3. Department of Biomedical Science and Advanced Therapies, Section of Hematology, University of Ferrara, Ferrara, Italy

    F. Lanza & M. Da Busti

Authors
  1. Massimo Gallerani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Manfredini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Donegà
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Lanza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Da Busti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. B. Vigna
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Fellin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Gallerani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gallerani, M., Manfredini, R., Donegà, P. et al. Adverse Haematological Effects of Ticlopidine. Clin. Drug Investig. 19, 231–237 (2000). https://doi.org/10.2165/00044011-200019030-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200019030-00008

Keywords

Search

Navigation